{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:04:28Z","timestamp":1790514268784,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.euroneuro.2019.11.008","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T09:57:23Z","timestamp":1575885443000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: A randomized controlled trial"],"prefix":"10.1016","volume":"31","author":[{"given":"Archana","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswa Ranjan","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monalisa","family":"Jena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santanu","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallabi","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2019.11.008_bib0001","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/13651501.2011.605954","article-title":"Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls","volume":"15","author":"Afonso","year":"2011","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0002","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.arcmed.2019.08.005","article-title":"Reversal of schizophrenia-like symptoms and cholinergic alterations by Melatonin","volume":"50","author":"Andrabi","year":"2019","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0003","first-page":"181","article-title":"Reduction of night\/day difference in melatonin blood levels as a possible disease-related index in schizophrenia","volume":"24","author":"Bersani","year":"2003","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0004","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11154-009-9125-5","article-title":"Melatonin formation in mammals: in vivo perspectives","volume":"10","author":"Chattoraj","year":"2009","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0005","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2165\/00023210-200822110-00004","article-title":"Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics","volume":"22","author":"Cohrs","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0006","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00213-003-1766-6","article-title":"Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects","volume":"174","author":"Cohrs","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0007","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jpsychires.2016.09.017","article-title":"Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs","volume":"84","author":"da Silva Araujo","year":"2017","journal-title":"J. Psychiatr Res."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0008","article-title":"Benzodiazepines for schizophrenia","volume":"11","author":"Dold","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.sleep.2005.09.004","article-title":"An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia","volume":"7","author":"Erman","year":"2006","journal-title":"Sleep Med."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF02246213","article-title":"A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia","volume":"117","author":"Goff","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0011","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0924-977X(96)00005-3","article-title":"Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjects","volume":"6","author":"Hajak","year":"1996","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0748730404269890","article-title":"Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats","volume":"20","author":"Hirai","year":"2005","journal-title":"J. Biol. Rhythms"},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0013","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archpsyc.63.10.1149","article-title":"Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects","volume":"63","author":"Johnson","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0014","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1507\/endocrj1954.33.405","article-title":"Nocturnal enhancement of plasma melatonin could be suppressed by benzodiazepines in humans","volume":"33","author":"Kabuto","year":"1986","journal-title":"Endocrinol. Jpn."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0015","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1074\/jbc.R600036200","article-title":"Arylalkylamine N-acetyltransferase: \"the timezyme\"","volume":"282","author":"Klein","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0016","first-page":"307","article-title":"The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland","volume":"52","author":"Klein","year":"1997","journal-title":"Recent Prog. Horm. Res."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0017","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/archpsyc.1989.01810100064012","article-title":"Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial","volume":"46","author":"Kramer","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0018","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/074873049701200622","article-title":"Melatonin: role in gating nocturnal rise in sleep propensity","volume":"12","author":"Lavie","year":"1997","journal-title":"J. Biol. Rhythms"},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0019","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/hup.1032","article-title":"Melatonin as a potential therapeutic agent in psychiatric illness","volume":"24","author":"Maldonado","year":"2009","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.psyneuen.2005.08.005","article-title":"Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine","volume":"31","author":"Mann","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0021","first-page":"701","article-title":"Augmentation with antidepressants in schizophrenia treatment: benefit or risk","volume":"11","author":"Mao","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0022","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.bcp.2009.10.004","article-title":"Good night and good luck: norepinephrine in sleep pharmacology","volume":"79","author":"Mitchell","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0023","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1755-5949.2008.00066.x","article-title":"Pharmacology of ramelteon, a selective MT1\/MT2 receptor agonist: a novel therapeutic drug for sleep disorders","volume":"15","author":"Miyamoto","year":"2009","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0024","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000119377","article-title":"Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics","volume":"36","author":"Monteleone","year":"1997","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.biopha.2017.05.094","article-title":"Melatonin attenuates behavioural deficits and reduces brain oxidative stress in a rodent model of schizophrenia","volume":"92","author":"Onaolapo","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0026","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5664\/jcsm.27282","article-title":"Circadian phase-shifting effects of repeated ramelteon administration in healthy adults","volume":"4","author":"Richardson","year":"2008","journal-title":"J. Clin. Sleep Med. JCSM: Off. Publ. Am. Acad. Sleep Med."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0027","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1600-0447.1991.tb03133.x","article-title":"Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients","volume":"84","author":"Robinson","year":"1991","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0028","doi-asserted-by":"crossref","first-page":"215","DOI":"10.9758\/cpn.2014.12.3.215","article-title":"Effects of add-on ramelteon on cognitive impairment in patients with schizophrenia: an open-label pilot trial","volume":"12","author":"Shirayama","year":"2014","journal-title":"Clin. Psychopharmacol. Neurosci. Off. Sci. J. Korean Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0029","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/17425255.2015.1045487","article-title":"Pharmacokinetic and pharmacodynamic evaluation of ramelteon: an insomnia therapy","volume":"11","author":"Spadoni","year":"2015","journal-title":"Exp. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4088\/JCP.v68n0208","article-title":"Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study","volume":"68","author":"Suresh Kumar","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0031","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1469-7793.2001.t01-1-00937.x","article-title":"Evidence for a biological dawn and dusk in the human circadian timing system","volume":"535","author":"Wehr","year":"2001","journal-title":"J. Physiol."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0032","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1192\/bjp.bp.111.096321","article-title":"Sleep and circadian rhythm disruption in schizophrenia","volume":"200","author":"Wulff","year":"2012","journal-title":"Br. J. Psychiatry: J. Mental Sci."},{"key":"10.1016\/j.euroneuro.2019.11.008_bib0033","first-page":"36","article-title":"Ramelteon: a novel hypnotic indicated for the treatment of insomnia","volume":"4","author":"Zammit","year":"2007","journal-title":"Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X19317614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X19317614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:55:30Z","timestamp":1760378130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X19317614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":33,"alternative-id":["S0924977X19317614"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.11.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}